• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DPx launched by JLL Partners, Royal DSM

DPx launched by JLL Partners, Royal DSM

March 12, 2014
CenterWatch Staff

JLL Partners and Royal DSM have launched DPx Holdings, a global contract development and manufacturing organization (CDMO) for the pharmaceutical and related industries.

DPx is the result of a $2.65 billion transaction between JLL Partners, a middle-market private equity firm, and Royal DSM, a global life sciences and materials sciences company. DPx is 51% owned by JLL Partners and 49% by Royal DSM. With headquarters in Durham, N.C., DPx’s global footprint includes 24 locations across North America, Europe, Latin America and Australia, and more than 8,000 employees.

Formerly known by its provisional name “NewCo,” DPx is the corporate parent of a group of business units comprised of three distinct brands focused on pharmaceutical services, fine chemicals and products and proprietary technologies. These units are the result of combining DSM Pharmaceutical Products (DPP), Patheon and Banner Life Sciences.

Pharmaceutical services will operate under the Patheon brand name and include the commercial manufacturing (CMO) capabilities, pharmaceutical product development services (PDS) and Biosolutions and Biologics (Bio) businesses of DPP. Fine Chemicals, or the ES/IM and active pharmaceutical ingredients (API) businesses, will operate under the brand name DSM Fine Chemicals. Proprietary products and technologies will operate under the Banner Life Sciences brand name.

Patheon is an end-to-end supplier providing an integrated supply chain model. Patheon delivers pharmaceutical development and manufacturing services ranging from API, biologics and biosolutions, as well as PDS and CMO capabilities. Additionally, DSM Fine Chemicals will handle complicated APIs and finished dosage forms for customers, while Banner Life Sciences will offer its own proprietary and nutraceutical products to the market.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing